Key result
Long-term (16 weeks) treatment with losartan effectively lowered systolic blood pressure and protected against stroke-induced brain damage in stroke-prone spontaneously hypertensive rats compared to vehicle and amlodipine.
Why the study?
Does losartan prevent brain damage and stroke more effectively than amlodipine in stroke-prone spontaneously hypertensive rats?
Does losartan prevent brain damage and stroke more effectively than amlodipine in stroke-prone spontaneously hypertensive rats?
p-value: p=<0.05
In a rat model of prehypertension, long-term losartan treatment provided superior protection against stroke and brain damage compared to amlodipine, mediated by reduced local RAAS activity.
Losartan may confer neuroprotection beyond BP control in hypertensive rats; leaves open translation to human stroke prevention.
Prehypertension has been associated with adverse cerebrovascular events and brain damage. The aims of this study were to investigate ⅰ) whether short‑ and long-term treatments with losartan or amlodipine for prehypertension were able to prevent blood pressure (BP)-linked brain damage, and ⅱ) whether there is a difference in the effectiveness of treatment with losartan and amlodipine in protecting BP-linked brain damage. In the present study, prehypertensive treatment with losartan and amlodipine (6 and 16 weeks treatment with each drug) was performed on 4-week‑old stroke-prone spontaneously hypertensive rats (SHRSP). The results showed that long-term (16 weeks) treatment with losartan is the most effective in lowering systolic blood pressure in the long term (up to 40 weeks follow-up). Additionally, compared with the amlodipine treatment groups, the short‑ and long-term losartan treatments protected SHRSP from stroke and improved their brains structurally and functionally more effectively, with the long-term treatment having more benefits. Mechanistically, the short‑ and long-term treatments with losartan reduced the activity of the local renin-angiotensin-aldosterone system (RAAS) in a time-dependent manner and more effectively than their respective counterpart amlodipine treatment group mainly by decreasing AT1R levels and increasing AT2R levels in the cerebral cortex. By contrast, the amlodipine treatment groups inhibited brain cell apoptosis more effectively as compared with the losartan treatment groups mainly through the suppression of local oxidative stress. Taken together, the results suggest that long-term losartan treatment for prehypertension effectively protects SHRSP from stroke-induced brain damage, and this protection is associated with reduced local RAAS activity than with brain cell apoptosis. Thus, the AT1R receptor blocker losartan is a good candidate drug that may be used in the clinic for long-term treatment on prehypertensive populations in order to prevent BP-linked brain damage.
No takes yet. Share an insight, caveat, or question.
He et al. (2013) studied Prehypertension (n=144). Losartan vs. Amlodipine or Vehicle was evaluated on Systolic blood pressure and clinical scores of stroke at 40 weeks (p=<0.05). Long-term (16 weeks) treatment with losartan effectively lowered systolic blood pressure and protected against stroke-induced brain damage in stroke-prone spontaneously hypertensive rats compared to vehicle and amlodipine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: